Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Raises Price Target to $40

HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Raises Price Target to $40

HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $36 to $40.

byBenzinga Newsdesk

February 21, 2023

1 minute read

HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $36 to $40.

Truist Securities Maintains Buy on Extra Space Storage, Raises Price Target to $225

By Benzinga Newsdesk

August 16, 7:04 AM

Truist Securities analyst Ki Bin Kim maintains Extra Space Storage (NYSE:EXR) with a Buy and raises the price target from $200 to $225.

EXR

BTIG Downgrades Applied Genetic to Neutral

By Benzinga Newsdesk

September 29, 5:07 AM

BTIG analyst Yun Zhong downgrades Applied Genetic (NASDAQ:AGTC) from Buy to Neutral.

AGTC

What’s Going On With Magna Shares After Incurring $316M Charges Related To Fisker In Q1?

By Nabaparna Bhattacharya

May 3, 8:48 AM

Magna International shares dip in premarket trading following Q1 results, including $316 million charges related to Fisker, despite beating revenue expectations and reporting increased adjusted EBIT.

FSRN

Cash Windfall For Avantax Stockholders – Stock Jumps On Buyout Deal

By Akanksha Bakshi

September 11, 10:00 AM

Avantax Inc. (NASDAQ: AVTA) has agreed to be acquired by Cetera Holdings for about

AVTA

HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Raises Price Target to $40

Related Posts

Truist Securities Maintains Buy on Extra Space Storage, Raises Price Target to $225

BTIG Downgrades Applied Genetic to Neutral

What’s Going On With Magna Shares After Incurring $316M Charges Related To Fisker In Q1?

Cash Windfall For Avantax Stockholders – Stock Jumps On Buyout Deal